News|Articles|July 6, 2026

Q2 2026 Recap: Psychiatry News & Updates

Fact checked by: Tim Smith

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Q2 2026 brought regulatory movement, phase 3 data, and structural change to depression care. The US Food & Drug Administration (FDA) expanded lumateperone (Caplyta) for schizophrenia relapse prevention, issued a complete response letter for Cingulate's CTx-1301 in ADHD, and saw a White House order accelerate psychedelic research for serious mental illness. Definium Therapeutics also reported phase 3 Emerge data showing DT120 (lysergide) produced rapid, durable relief in major depressive disorder (MDD).